Lead Investigator, Amplia Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| Lead Investigator | Amplia Therapeutics | SMH Business, The Age Business |
Stories naming Dr Gwo Yaw Ho. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Amplia has locked in the design of its PRROSE phase two study pairing narmafotinib with chemotherapy in ovarian cancer, to run with ANZGOG across Australia and New Zealand, recruiting about 26 patients.
Biotech Amplia Therapeutics has completed planning for its PRROSE phase two trial pairing narmafotinib with chemotherapy in ovarian cancer, working with ANZGOG, with patient recruitment targeted before the end of 2026.